Investor Presentation First Nine Months of 2022
Therapy
areas
28
Investor presentation First nine months of 2022
Core capabilities and additional technology platforms open up
new opportunities across therapy areas
Diabetes care
Obesity care
CVD
NASH
RBD
RED
Other areas
m
Technology platforms
O
Proteins / Peptides Oligonucleotides / RNAi Stem cells Genome editing / Gene therapy
20
20
Currently active
Q0
110
110
10
CO
114
110
O
Note: Currently active means Novo Nordisk is currently pursuing research projects, while exploratory potential indicates that the platform is potentially applicable for the given disease
RBD: Rare blood disorders; RED: Rare endocrine disorders; CVD: Cardiovascular disease; NASH: Non-alcoholic steatohepatitis; RNA: Ribonucleic acid
Exploratory potential
10
O
O
O
O
Tal
110
O
1
Injectable administration
B
Oral administration
Novo NordiskⓇView entire presentation